What began as an outing to celebrate his graduation from college at the age of 21, turned into a full time position and hobby for Ben Lowe. 591 jumps later he still feels the exhilaration of the jump, the 120 mile per hour wind against his face and the near minute of free-fall. But the risk taking doesn’t stop there for Ben, he also loves to BASE jump. Cliffs, bridges, mountain tops . . . you name it, he’ll jump from it. Visit Ben on MOLI.com
An international team of researchers led by Gerard D. Schellenberg, PhD, a member of the CurePSP Genetics Consortium and professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania, has identified three new genes that can increase the risk of people developing Progressive Supranuclear Palsy (PSP).
PSP is a rare neurodegenerative brain disease, similar to Parkinson’s disease, which causes severe disability by destroying parts of cells that allow the brain to function normally. While PSP has underlying biological similarities to Alzheimer’s disease, a disease which primarily affects memory, PSP impacts a person’s physical movement and bodily functions. PSP leads to progressive decline in patients — there is no known cause or cure.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/psp/49958/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and haemodynamic monitoring, announced the results of a pivotal clinical study of high-risk surgical patients with severe aortic stenosis treated in Cohort A of The PARTNER Trial. These data demonstrate that the study achieved its primary endpoint at one year, concluding that survival of patients treated with the Edwards SAPIEN transcatheter aortic valve was equivalent to those treated with surgical aortic valve replacement. The data were presented at the American College of Cardiology’s (ACC) 60th Annual Scientific Session & Expo in New Orleans, LA, USA.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/48895/
Pregnancy is an exciting time filled with hopeful anticipation, and most pregnancies are uneventful and result in healthy babies. Pregnancy, however, is not entirely without risk, leading some expectant parents to worry about birth defects and whether they’ll give birth to a healthy baby.
Many birth defects are minor and easily treated. But about one in every 33 babies is born with a major birth defect, according to the Centers for Disease Control. Major birth defects may have a serious impact on development, functional ability and overall health. Throughout January, which is Birth Defects Prevention Month, BeSmartBeWell.com highlights pregnancy risks and preventable birth defects. At BeSmartBeWell.com medical experts, and real-life expectant moms, like Sharon, share information to help lower the risk for birth defects.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/birthdefects/50829/
From bestselling Wicked authors Nancy Holder and Debbie Viguie comes a new series: Crusade. In the first book in the series, the Cursed Ones, vampires, have declared war on humanity. Most people are too afraid or otherwise unwilling to take a stand. Others, like eighteen year old Jenn Leitner, train to become vampire fighters and risk everything in the process. Learn more about this book: http://bit.ly/aTDMCA Learn more about these authors: http:///www.nancyholder.com and http://www.debbieviguie.com YA
http://www.babysleepsolution.com Useful tips on how parents can reduce the risk of SIDS or Cot Death. Baby sleep safety tips.
Baby sleep safety
Baby sleep problems
Baby sleep information
National health initiative DRIVE4COPD today announced the launch of its new Ambassador Program, which gives fans the opportunity to join their favorite celebrity in a common cause: raising awareness of chronic obstructive pulmonary disease (COPD). The Ambassador Program marks the beginning of the Great American Screen Off, a nationwide push this fall to screen Americans for their risk of COPD at DRIVE4COPD.COM. Fans can now enter the DRIVE4COPD Celebrity Race Team’s ongoing competition to see who can screen the most people.
To view Multimedia News Release, go to http://www.multivu.com/players/English/46007-boehringer-ingelheim-great-american-screen-off/
http://wlwsingles.com/ecb-exchange-rates-2/
Euro Zone Decline Continues
Last week the risk appetite that had dominated currency markets for the previous two weeks came to an abrupt halt. In spite of warnings from professionals that economic optimism was premature numerous investors and traders adopted the
Summer is right around the corner and although we wear sunscreen to protect our skin we often forget about our eyes. Women of color are at higher risk for vision complications which can be linked to UV exposure. Transitions® lenses automatically change from clear indoors to dark outdoors, blocking harmful UV rays and reducing glare, and they can be fitted with your favorite designer frame styles.
The Rock and Roll Acid Test is more than just a show. Its an adrenaline injected, rock fueled perversion of the scientific method. Your hosts will risk bodily harm to prove or disprove some of rocks most enduring myths. Dont miss all the educational fun! And explosions! Did I mention there are explosions? PREMIERES TUESDAY JUNE 17th at 10pm ET on FUSE.
The Sounds of Pertussis Campaign moves into action with the second annual Pertussis Awareness Day in New York City featuring a range of educational activities, including the launch of the Sound Off About Pertussis song contest and a new public service announcement (PSA) featuring four-time NASCAR Sprint Cup Series champion Jeff Gordon. The national public awareness campaign encourages parents to help protect themselves and their babies from pertussis—commonly known as whooping cough—by getting vaccinated with an adult Tdap (tetanus, diphtheria, acellular pertussis) booster, which may reduce their risk of getting the disease and spreading it to their babies.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/soundsofpertussis/45203/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
